🚀 VC round data is live in beta, check it out!
Heartseed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Heartseed and similar public comparables like Prelude Therapeutics, Achieve Life Sciences, SAB Bio, Compugen and more.
Heartseed Overview
About Heartseed
Heartseed Inc is a Japanese biotechnology company focused on developing and commercializing regenerative medicine treatments for severe heart failure. The company's product candidate, HS-001, involves transplanting clusters of purified heart muscle cells derived from iPSCs to the patient's heart to treat heart failure, especially Heart Failure with reduced Left Ventricular Ejection Fraction (HFrEF), including conditions such as Dilated Cardiomyopathy, Old Myocardial Infarction, and Dilated phase of Hypertrophic Cardiomyopathy.
Founded
2015
HQ
Employees
42
Website
Sectors
Financials (LTM)
EV
$233M
Heartseed Financials
Heartseed reported last 12-month revenue of $15M.
In the same LTM period, Heartseed generated had net loss of ($1M).
Revenue (LTM)
Heartseed P&L
In the most recent fiscal year, Heartseed reported revenue of $19M and EBITDA of $2M.
Heartseed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $19M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 98% | XXX | XXX | XXX |
| EBITDA | — | XXX | $2M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | (6%) | XXX | 24% | XXX | XXX | XXX |
| Net Profit | ($1M) | XXX | $4M | XXX | XXX | XXX |
| Net Margin | (9%) | XXX | 20% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Heartseed Stock Performance
Heartseed has current market cap of $276M, and enterprise value of $233M.
Market Cap Evolution
Heartseed's stock price is $12.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $233M | $276M | -0.7% | XXX | XXX | XXX | $0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHeartseed Valuation Multiples
Heartseed trades at 16.1x EV/Revenue multiple, and 108.6x EV/EBITDA.
EV / Revenue (LTM)
Heartseed Financial Valuation Multiples
As of April 18, 2026, Heartseed has market cap of $276M and EV of $233M.
Equity research analysts estimate Heartseed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Heartseed has a P/E ratio of (201.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $276M | XXX | $276M | XXX | XXX | XXX |
| EV (current) | $233M | XXX | $233M | XXX | XXX | XXX |
| EV/Revenue | 16.1x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 108.6x | XXX | XXX | XXX |
| EV/EBIT | (271.1x) | XXX | 50.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 12.3x | XXX | XXX | XXX |
| P/E | (201.1x) | XXX | 72.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 35.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Heartseed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Heartseed Margins & Growth Rates
Heartseed's revenue in the last 12 month declined by (86%).
Heartseed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Heartseed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (86%) | XXX | (85%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (158%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 89% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Heartseed Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Heartseed | XXX | XXX | XXX | XXX | XXX | XXX |
| Prelude Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Achieve Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| SAB Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Compugen | XXX | XXX | XXX | XXX | XXX | XXX |
| Antibiotice | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heartseed M&A Activity
Heartseed acquired XXX companies to date.
Last acquisition by Heartseed was on XXXXXXXX, XXXXX. Heartseed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Heartseed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHeartseed Investment Activity
Heartseed invested in XXX companies to date.
Heartseed made its latest investment on XXXXXXXX, XXXXX. Heartseed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Heartseed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Heartseed
| When was Heartseed founded? | Heartseed was founded in 2015. |
| Where is Heartseed headquartered? | Heartseed is headquartered in Japan. |
| How many employees does Heartseed have? | As of today, Heartseed has over 42 employees. |
| Is Heartseed publicly listed? | Yes, Heartseed is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Heartseed? | Heartseed trades under 219A ticker. |
| When did Heartseed go public? | Heartseed went public in 2024. |
| Who are competitors of Heartseed? | Heartseed main competitors are Prelude Therapeutics, Achieve Life Sciences, SAB Bio, Compugen. |
| What is the current market cap of Heartseed? | Heartseed's current market cap is $276M. |
| What is the current revenue of Heartseed? | Heartseed's last 12 months revenue is $15M. |
| What is the current revenue growth of Heartseed? | Heartseed revenue growth (NTM/LTM) is (86%). |
| What is the current EV/Revenue multiple of Heartseed? | Current revenue multiple of Heartseed is 16.1x. |
| Is Heartseed profitable? | No, Heartseed is not profitable. |
| What is the current net income of Heartseed? | Heartseed's last 12 months net income is ($1M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.